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R Scott Braithwaite1* and Matthew Scotch2Abstract
Background: Decision support systems for differential diagnosis have traditionally been evaluated on the basis of
criteria how sensitively and specifically they are able to identify the correct diagnosis established by expert clinicians.
Discussion: This article questions whether evaluation criteria pertaining to identifying the correct diagnosis are most
appropriate or useful. Instead it advocates evaluation of decision support systems for differential diagnosis based on
the criterion of maximizing value of information.
Summary: This approach quantitatively and systematically integrates several important clinical management priorities,
including avoiding serious diagnostic errors of omission and avoiding harmful or expensive tests.
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In clinical care, there has been much effort on decreasing
medical errors including diagnostic errors of omission
(DEO). In fact, DEOs account for a large proportion of
medical adverse events and form the second-leading cause
for malpractice suits against hospitals [1]. Improving dif-
ferential diagnostic (DDX) decision support tools has great
potential to reduce DEOs [2-4]. However, DDX decision
support tools are often constructed with the goal of identi-
fying a single correct diagnosis, which does not necessarily
diminish DEOs unless the tool has optimal performance
characteristics. This article discusses whether an alter-
native criterion for evaluating DDX tools, in particular
maximization of value of information [5], might yield
DDX tools that are more effective at reducing DEOs [1,6],
than ones designed to detect the best diagnosis [4,7-11].
Discussion
The value of DDX tools
Decision support tools exist to facilitate better decisions,
and better health decisions are those choices that
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article, unless otherwise stated.patient preferences and principles of shared decision
making [12]. Accordingly, value of information (VOI)
may be a particularly suitable framework for evaluating
DDX decision support tools. This is because it considers
the monetarized benefit of morbidity and mortality that
can be prevented through improvements in decisions
that are made possible by new information, after consid-
ering the costs and harms of obtaining that information.
In the context of DDX decision support tools, applying
VOI can be viewed as a quantitative means of integrat-
ing several desirable goals. These include maximizing
the morbidity and mortality of DEOs that may be
averted by DDX tools, and minimizing the incremental
costs and harms from the diagnostic tests that these
tools may induce.
Brief summary of VOI
VOI is a framework developed by Claxton [5,13] that has
its conceptual roots in decision analysis and economics. A
detailed description of VOI is beyond the scope of this
paper. However, VOI assessment of an informatics inter-
vention can be viewed as a three-step mathematical calcu-
lation: (1) “How would health outcomes change because
of different decision making that would result from using
the intervention?”, (2) “What is the monetarized value of
that change in health outcomes?” and (3) “How does #2ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Braithwaite and Scotch BMC Medical Informatics and Decision Making 2013, 13:105 Page 2 of 5
http://www.biomedcentral.com/1472-6947/13/105change after considering the costs of the intervention
and considering the downstream consequences of its
use?” Accordingly, if health outcomes would be im-
proved by the post-intervention decision making com-
pared to the pre-intervention decision making, (question
1), the expected value of information (EVI) would be nu-
merically higher (or less negative) (question 2). However,
if incremental costs of using the intervention are greater
than those of not using the intervention including differ-
ences in diagnostic tests ordered and their downstream
consequences (including false positives and complica-
tions), then the EVI would be numerically lower or more
negative (question 3).
Illustrative scenario
Consider a 64 year-old man who presents to an emer-
gency department with severe chest pain but without
dyspnea or other pain. While there are literally hun-
dreds of potential diagnoses that could be considered
by a DDX tool, the tool is most clinically useful if it
initially restricts its attention to the subgroup of those
diagnosis that are “actionable”. Here, “actionable” re-
fers to a situation in which rapidly identifying a par-
ticular diagnosis could lead to decisions that would
improve morbidity and mortality. Conversely, delaying
the identification of that diagnosis would lead to de-
cisions that worsened morbidity and mortality. This
definition is similar to Ramnarayan’s definition of
“clinically relevant diagnoses” [1] but can be specified
in terms of morbidity and mortality, and therefore is
more closely linked to VOI. (“Actionability” can be de-
fined as the expected value (EV) of rapid treatment
minus the EV of delayed or no treatment. It is a dis-
tinct concept from “import” [14], which is an approxi-
mation of the true positivity of a test with respect to a
disease in the differential diagnosis, and does not ne-
cessarily contain any information about the incremen-
tal morbidity and mortality that may be prevented by a
timely diagnosis.) For example, diagnoses of myocar-
dial infarction, pulmonary embolism, dissecting aortic
aneurysm, and pericarditis would be highly actionable
because of the morbidity and mortality burden that
could be mitigated through prompt action. On the
other hand, diagnosis of non-dyspneic pleuritis would
be less actionable because potential mechanisms of
pleuritis (e.g. malignancies), while capable of causing
serious morbidity and mortality, would not necessarily
lead to great reductions in morbidity and mortality by
quick identification and response. Similarly, other pos-
sible diagnoses such as panic attacks, neuralgic pain
from zoster or pain from costochrondritis would be
even less actionable, unless it dramatically reduced the
probability of an actionable diagnosis through consid-
erations of physiological incompatibility.Relationship between VOI criteria and DDX decision
support tools
Consider two similar scenarios in which the 64 year-old
man described above presents to the emergency depart-
ment with chest pain, one of which is caused by a diagno-
sis that is extremely actionable (Figure 1, scenario i), and
another that is caused by a diagnosis that is only slightly
actionable (Figure 1, scenario ii). With both scenarios, a
more clinically useful DDX tool would more rapidly
maximize increments in EVI. In the first scenario, in
which the chest pain has an actionable diagnosis, the tool
would guide decision making to rapidly accurately identify
the actionable cause of chest pain, thereby leading to the
improvements in morbidity and mortality that could ele-
vate EVI (Figure 1, scenario i). In the second scenario, in
which the chest pain does not have an actionable etiology
(Figure 1, scenario ii), the tool would guide decision mak-
ing to rapidly and accurately rule-out the actionable
causes of chest pain (Figure 1, scenario ii), or, if feasible, to
rapidly rule-in a non-actionable diagnosis that is incom-
patible with the actionable diagnoses. As evaluated by
EVI, better DDX decision support tools would be those
that lead to clinical management strategies that avoid
diagnostic resources that do not end up reducing prevent-
able morbidity and mortality. Because not all diagnostic
tests can occur simultaneously, the ideal DDX decision
strategy tool will guide ordering of diagnostic tests to
maximize EVI, and may even sometimes increase EVI
fastest by ruling-in a common diagnosis with lower pre-
ventable morbidity and mortality that is incompatible with
a rarer diagnosis with higher preventable morbidity and
mortality (Figure 2).
Limitations of prior efforts to use VOI to evaluate DDX
Downs et al. (1997) first proposed applying a VOI to
evaluate DDX processes [15]. However, their approach
had multiple limitations which our current approach im-
proves upon, and therefore our approach may be more
feasible. First, they calculated VOI using utilities that
were not elicited using standard decision analytic ap-
proaches for health states (e.g., time tradeoff ) [16], and
consequently their VOI calculations did not necessarily
reflect potential morbidity and mortality improvement.
For example, viral pneumonia correctly diagnosed was
given a higher utility than bacterial pneumonia correctly
diagnosed, even though correct diagnosis of bacterial
pneumonia would be expected to improve quality and
quantity of life, and therefore to improve health-state
based utility, much more than correct diagnosis of viral
pneumonia. In contrast, we suggest using health state-
based utilities, which comport more readily with appli-
cations of VOI to medical decision making.
Second, their approach yielded the unrealistic result
that the VOI of most information-seeking was zero
Figure 1 (See legend on next page.)
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Figure 1 Scenarios where true diagnosis is actionable (i) versus inactionable (ii). “Actionability” refers to the idea that rapid identification
can reduce preventable morbidity and mortality compared to delayed identification. When the true diagnosis is actionable (scenario “i”), the
perfect diagnostic strategy instantaneously actuates the increment in EVI made possible by ascertaining that diagnosis, at minimal cost. When the
true diagnosis is inactionable (scenario “ii”), the perfect diagnostic strategy minimizes decrements in EVI associated with ruling out other
diagnoses because of harms and/or costs associated with diagnostic tests. EVI: expected value of information.
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information gathering: time, patient discomfort, and com-
plications. All of these would be expected to lead to a
negative VOI even when no informative diagnostic infor-
mation is produced. Although they attempted to address
the limitation subsequently [17] by modifying their VOI
algorithm to “calculate the average of the expected utility
across all the diagnoses, then subtract the expected utility
of the diagnosis with the highest utility”, this modification
presumes that VOI reflects changes in the EV of particular
diseases more directly than changes in the EV of the most
favored decision, unlike subsequent uses of VOI [5]. In
contrast, we recommend valuating negative as well as
positive consequences of additional information gathering,
and we advocate using VOI based on the EV of the most
favored decision [5].
Third, their approach does not identify a point at which
the diagnostic process should naturally stop, which is a
concept with great clinical value. If most of the informa-
tion comprising the diagnostic process has an EVI of zero,
the diagnostic process could go on indefinitely. In con-
trast, because we consider negative EVIs, a decline in
the EVI curve would be expected to occur at some point
(for example, when clinicians are adopting “shotgun”Possible 
diagnosis 1 
Possible 
diagnosis 2 
Possible 
diagnosis 3 
Possible 
diagnosis 4 
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Figure 2 The expected value of information of differential diagnostic
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possibilities (left column) are updated by diagnostic tests to produce upda
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proceed in the opposite direction, increasing the likelihood of diagnoses w
EVI. Costs associated with the diagnostic tests lower EVI (shown here by th
as that which maximizes EVI. EVI: expected value of information.diagnostic strategies that may have side effects), signaling
that the diagnostic phase should conclude.
Possible VOI metrics for assessing performance of DDX
decision support tools
An ideal diagnostic process would minimize preventable
morbidity and mortality to the patient, and would also
minimize cost, time, and discomfort. The value of EVI at
the end of the diagnostic process is a candidate for
distinguishing a more favorable diagnostic trajectory
from a less favorable diagnostic strategy and clinical
management. For example, compare the EVI endpoint
for an optimal diagnostic pathway (Curves C in Figure 1)
compared to the EVI endpoint for typical, unaided diag-
nostic pathway (Curves A in Figure 1). A DDX decision
support tool that leads to a greater proportional reduc-
tion, and therefore raises the EVI endpoint of Curve A
closer to that of Curve C, would be preferred to a DDX
tool that leaves the VOI endpoint of Curve A more dis-
tant from Curve C. Alternatively, area under the curve
EVI might also be a suitable metric for assessing the per-
formance of DDX tools. It is important to note that sim-
ply ordering all tests simultaneously to get rapid results
would not optimize an EVI endpoint, because thePossible 
diagnosis 1 
Possible 
diagnosis 2 
Possible 
diagnosis 3 
Possible 
diagnosis 4 
Cost of gaining 
new information at 
time 2
TION
y time,
d specificity
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tools. The EVI of DDX tools is based on the monetarized value of the
agnosis, multiplied by the probability of that diagnosis, minus costs
t modify the probability of that diagnosis. The prior diagnostic
ted diagnostic probabilities (right column). The updating here increases
ortality, therefore increasing EVI. However, the updating could
ith lesser preventable morbidity and mortality, therefore, decreasing
e red arrows). An optimal DDX decision support tool could be viewed
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tests would lower the EVI trajectory.
Limitations of VOI-optimized DDX tools
A DDX decision support tool optimized using VOI criteria
would need to consider whether it is feasible to address
more than one actionable diagnosis simultaneously, and
this answer might vary for logistical reasons (e.g. number
of operational CT scanners) between settings, institutions,
and even between different shifts at the same institutions.
For example, a DDX tool would need to factor in the pos-
sibility that it may be impossible to rule-out a myocardial
infarction and a dissecting aortic aneurysm at a particular
facility the same time, and therefore the DDX tool would
ideally have the capability to guide prioritization of diag-
nostic decisions in accord with their relative increase in
EVI. Further limitations of VOI-optimized DDX tools in-
clude an absence of a clear path towards enhancing shared
decision making or considering individual patient prefer-
ences, and a potential lack of engagement with the types
of cognitive errors and biases that lead to suboptimal deci-
sion making in the first place [18].
Summary
Whether a DDX decision support tool gets the diagnosis
right may not be as important as whether the tool is able to
reduce preventable morbidity and mortality by reducing
DOEs. VOI analyses in general, and EVI trajectories in par-
ticular, may be useful metrics for evaluating whether a
DDX tool is able to pursue the important objective of redu-
cing DOEs as well as other important objectives pertaining
to minimizing harm and unnecessary expenditures.
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